TQB2210 / Sino Biopharm - LARVOL DELTA

Clinical Trial to Evaluate the Tolerance of TQB2210 Injection (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | N=90 ➔ 16 | Trial completion date: Apr 2027 ➔ Apr 2026 | Trial primary completion date: Apr 2027 ➔ Apr 2026

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Clinical Trial to Evaluate the Tolerance of TQB2210 Injection (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Clinical Trial to Evaluate the Tolerance of TQB2210 Injection (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Solid Tumor